Indaptus Therapeutics, Inc. (NASDAQ:INDP – Free Report) – Equities research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Indaptus Therapeutics in a note issued to investors on Monday, April 15th. HC Wainwright analyst R. Selvaraju forecasts that the company will earn ($0.38) per share for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Indaptus Therapeutics’ current full-year earnings is ($1.73) per share. HC Wainwright also issued estimates for Indaptus Therapeutics’ Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS and FY2025 earnings at ($1.44) EPS.
Indaptus Therapeutics (NASDAQ:INDP – Get Free Report) last issued its quarterly earnings data on Wednesday, March 13th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.07.
Indaptus Therapeutics Stock Down 4.7 %
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of INDP. Citadel Advisors LLC bought a new stake in shares of Indaptus Therapeutics in the fourth quarter valued at about $29,000. Northern Trust Corp purchased a new stake in Indaptus Therapeutics in the first quarter valued at approximately $41,000. Renaissance Technologies LLC purchased a new stake in Indaptus Therapeutics in the 2nd quarter worth approximately $51,000. State Street Corp purchased a new stake in Indaptus Therapeutics in the 1st quarter worth approximately $78,000. Finally, Vanguard Group Inc. boosted its position in Indaptus Therapeutics by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 256,265 shares of the company’s stock worth $451,000 after purchasing an additional 5,517 shares in the last quarter. 7.06% of the stock is owned by hedge funds and other institutional investors.
Indaptus Therapeutics Company Profile
Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.
See Also
- Five stocks we like better than Indaptus Therapeutics
- What is an Earnings Surprise?
- United Airlines Soars on Earnings Beat
- Why is the Ex-Dividend Date Significant to Investors?
- J.B. Hunt Hits the Skids: Lower Prices to Come
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.